全国首款！天竺综保区引入“全球最小的心脏泵”

Core Insights - The introduction of the Johnson & Johnson Impella heart pump marks a significant advancement in the treatment of critical heart diseases in China, being the first clinically urgent medical device approved for importation [1][3] - The successful signing at the China International Import Expo highlights the collaboration between various governmental and healthcare entities to facilitate the import of this life-saving technology [1][3] Group 1: Product and Market Impact - The Impella heart pump is the only FDA-approved device of its kind globally, designed for patients undergoing high-risk PCI procedures or experiencing cardiogenic shock, providing effective circulatory support and improving survival rates [3] - The import of the Impella pump is seen as a model for accelerating the introduction of more innovative overseas medical devices and drugs into the Chinese market, ultimately benefiting domestic patients [3] Group 2: Policy and Future Developments - The Tianzhu Comprehensive Bonded Zone is rapidly advancing its Rare Disease Drug Guarantee Pilot Zone, aiming to facilitate the import of more urgently needed medical products [4] - The initiative is part of a broader strategy to enhance the pharmaceutical industry in Beijing, ensuring that critical medical supplies can be imported efficiently to meet public health needs [4]